A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)

Summary

The purpose of this study is to evaluate the efficacy of ustekinumab compared to placebo, in combination with oral glucocorticoid (GC) taper regimen, in participants with relapsing Takayasu Arteritis (TAK).

Timeline

Start

2021-09-15

Primary completion

2023-05-25

Completion

2023-05-25

Publications

• Yoshifuji H, Ishii T, Ohashi H, Yoshizawa K, Mihoya M, Nishikawa K, Nakaoka Y. Phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study of ustekinumab in patients with Takayasu arteritis. Rheumatol Adv Pract. 2025 Feb 3;9(2):rkaf013. doi: 10.1093/rap/rkaf013. eCollection 2025.

Drugs

Indications